KYNB

KYNTRA BIO INC

• TipRanks·03/18 00:05

  FibroGen Earnings Call: Cash-Rich, Data-Heavy, Unproven

• NASDAQ·03/17 10:26

  Kyntra Bio Q4 And FY25 Revenue Declines; On Track For Phase 2 Trial Analysis Of FG-3246 In H2,2026

• TipRanks·03/17 10:16

  Advancing Pipeline and 2026 Clinical Catalysts Underpin Buy Rating on Kyntra Bio

• TipRanks·03/16 22:55

  Maintaining a Hold on Kyntra Bio Amid Pipeline Refocus and Pending Clinical Inflection Points

• Reuters·03/16 20:25

  Kyntra Bio Inc. publishes investor presentation on its prostate cancer FG-3246 and roxadustat programs and USD 220 million FibroGen China sale

• Dow Jones·03/16 20:22

  *Kyntra Bio: Phase 2 Monotherapy Trial of FG-3246 Actively Enrolling and Remains on Track for Interim Analysis in 2H

• Seeking Alpha·03/16 20:04

  FibroGen GAAP EPS of -$3.51 beats by $0.37, revenue of $1.27M misses by $0.4M

• Benzinga·03/16 20:03

  Kyntra Bio Q4 EPS $(3.61) Beats $(3.71) Estimate, Sales $1.300M Miss $1.425M Estimate

• Reuters·03/16 20:03

  Kyntra Bio Q4 2025 net loss rises 67.97% to USD 14.6 million as revenue falls 59.25% to USD 1.28 million

• Dow Jones·03/16 20:03

  *Kyntra Bio Has Cash, Cash Equivalents, Investments, and Accounts Receivable of $109.4 M, Providing Cash Runway Into 2028

• Dow Jones·03/16 20:03

  *Kyntra Bio 4Q Rev $1.28M >KYNB

• Dow Jones·03/16 20:03

  *Kyntra Bio 4Q Loss $14.2M >KYNB

• Reuters·03/16 20:02

  KYNTRA BIO INC - Q4 EPS $-3.51

• Reuters·03/16 20:02

  KYNTRA BIO INC - PHASE 2 FG-3246 TRIAL IN MCRPC ENROLLING, INTERIM ANALYSIS EXPECTED 2H 2026

• Dow Jones·03/16 20:02

  Press Release: Kyntra Bio Reports Fourth Quarter -2-